Tweet
Bird flu information extracted
Sydney Morning Herald, Australia - <nobr>Aug 29, 2008</nobr>
Appendix 4E Preliminary Final Report Of This Preliminary Final Report is provided to the Australian Securities Exchange (ASX) under ASX Listing Rule 4.3A
Review of Operations
2008 marks a year of transition for the Group in its efforts to diversify its activities into lifestyle health products, namely Pepp?, whilst continuing to maintain and grow the rapid testing product division.
Since the launch of Pepp? a year ago, the Group recorded sales of more than 600,000, units predominantly in Singapore and China, as at the end of June 2008
The seasonality of the bird flu outbreaks has resulted in decreased sales of the bird flu tests for the year.
However, the Group believes that the medium to long term outlook for the sale of bird flu tests remain strong.
Avian Influenza Diagnostics
The seasonality of the bird flu outbreaks has resulted in decreased sales of the bird flu tests during the year.
The Group continued with its business development efforts in the markets for Avian flu tests. This has resulted in the ability to procure for tenders in Middle East, Tunisia and Brunei Darussalam.
The Group is proud to collaborate with several government institutions around the world to provide a cost effective and reliable method to monitor bird flu.
The acquisition of a 40% interest in Anheal which was announced in November 2006 has taken longer than expected to complete as Anheal, a Chinese government-linked company, was required to undergo a national audit....The Group believes that Anheal will provide direct access to China * the world's largest poultry market for its Avian Influenza Virus diagnostic test.
New Research and & Development Grants
The Group presented its Proof of Concept to demonstrate the use magnetic detection for a rapid and sensitive test for the diagnosis of Influenza A, including avian influenza, on 15 August 2008. The total amount being applied for under this first grant is S$250,000 (A$190,000).
Financial Position
The Group expects to improve its performance in the new financial year mainly through improved Avian Flu tests and Pepp sales. Subsequent to year end, the Group received orders for Avian Flu tests and Pepp worth approximately A$700,000.
Subsequent Events
On 24th July 2008, the Group announced that it had received bird flu test orders worth USD230,000 (AUD242,000) from several South East Asian, European and North African countries. The entire payment for these orders has been received and the shipments have either been made or are in progress. The Group is pleased to be recognised by governments around the globe for supplying a cost effective and reliable form of monitoring of bird flu.
In the same announcement on 24th July 2008, the Group also informed its shareholders that it had decided to withdraw from the non-binding MOU for the supply of bird flu tests with a South East Asian country as announced on 31st January 2008. This decision was made on the basis that to date, the Group had not received payment (in advance) for the first order, as stipulated in the MOU. The Group assured shareholders that there was no financial loss as a result of this decision as there was no prior cash outl
ABOUT ROCKEBY
Rockeby biomed Limited is a Singapore-based, ASX-listed (ASX: RBY) healthcare company specialising in research, development and marketing of rapid testing technologies for infectious disease in humans and animals and lifestyle health products including CanDia5?, Avian Influenza Virus test kits and Pepp
Sydney Morning Herald, Australia - <nobr>Aug 29, 2008</nobr>
Appendix 4E Preliminary Final Report Of This Preliminary Final Report is provided to the Australian Securities Exchange (ASX) under ASX Listing Rule 4.3A
Review of Operations
2008 marks a year of transition for the Group in its efforts to diversify its activities into lifestyle health products, namely Pepp?, whilst continuing to maintain and grow the rapid testing product division.
Since the launch of Pepp? a year ago, the Group recorded sales of more than 600,000, units predominantly in Singapore and China, as at the end of June 2008
The seasonality of the bird flu outbreaks has resulted in decreased sales of the bird flu tests for the year.
However, the Group believes that the medium to long term outlook for the sale of bird flu tests remain strong.
Avian Influenza Diagnostics
The seasonality of the bird flu outbreaks has resulted in decreased sales of the bird flu tests during the year.
The Group continued with its business development efforts in the markets for Avian flu tests. This has resulted in the ability to procure for tenders in Middle East, Tunisia and Brunei Darussalam.
The Group is proud to collaborate with several government institutions around the world to provide a cost effective and reliable method to monitor bird flu.
The acquisition of a 40% interest in Anheal which was announced in November 2006 has taken longer than expected to complete as Anheal, a Chinese government-linked company, was required to undergo a national audit....The Group believes that Anheal will provide direct access to China * the world's largest poultry market for its Avian Influenza Virus diagnostic test.
New Research and & Development Grants
The Group presented its Proof of Concept to demonstrate the use magnetic detection for a rapid and sensitive test for the diagnosis of Influenza A, including avian influenza, on 15 August 2008. The total amount being applied for under this first grant is S$250,000 (A$190,000).
Financial Position
The Group expects to improve its performance in the new financial year mainly through improved Avian Flu tests and Pepp sales. Subsequent to year end, the Group received orders for Avian Flu tests and Pepp worth approximately A$700,000.
Subsequent Events
On 24th July 2008, the Group announced that it had received bird flu test orders worth USD230,000 (AUD242,000) from several South East Asian, European and North African countries. The entire payment for these orders has been received and the shipments have either been made or are in progress. The Group is pleased to be recognised by governments around the globe for supplying a cost effective and reliable form of monitoring of bird flu.
In the same announcement on 24th July 2008, the Group also informed its shareholders that it had decided to withdraw from the non-binding MOU for the supply of bird flu tests with a South East Asian country as announced on 31st January 2008. This decision was made on the basis that to date, the Group had not received payment (in advance) for the first order, as stipulated in the MOU. The Group assured shareholders that there was no financial loss as a result of this decision as there was no prior cash outl
ABOUT ROCKEBY
Rockeby biomed Limited is a Singapore-based, ASX-listed (ASX: RBY) healthcare company specialising in research, development and marketing of rapid testing technologies for infectious disease in humans and animals and lifestyle health products including CanDia5?, Avian Influenza Virus test kits and Pepp